博腾股份(300363) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the reporting period was ¥698,256,521, a decrease of 46.44% year-on-year, and total revenue for the year-to-date was ¥3,037,002,978.71, down 41.79% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥41,486,354.40, representing a decline of 88.65% year-on-year, while the year-to-date net profit was ¥451,859,325.20, down 71.36% compared to the previous year[3]. - The gross profit margin for the company was 46%, a decrease of 6.56 percentage points year-on-year, and the net profit margin was 11.93%, down 16.96 percentage points year-on-year[11]. - The company achieved operating revenue of CNY 3.037 billion in the first three quarters of 2023, a decrease of 41.79% compared to CNY 5.218 billion in the same period of 2022[28]. - The net profit for the current period was approximately 362 million yuan, compared to approximately 1.51 billion yuan in the previous period, reflecting a decline of about 76%[45]. - The total comprehensive income for the period is CNY 356,907,696.86, compared to CNY 1,481,856,234.50 for the same period last year[50]. - The net income attributable to the parent company is CNY 446,323,547.54, down from CNY 1,552,026,963.25 year-over-year[50]. - Basic earnings per share for the period is CNY 0.83, compared to CNY 2.90 in the previous year[50]. Cash Flow and Assets - The company’s cash flow from operating activities for the year-to-date was ¥938,413,241.57, a decrease of 59.26% compared to the same period last year[3]. - The company's cash and cash equivalents decreased to ¥2,121,071,293.51 from ¥2,850,419,010.56, reflecting a reduction of about 25.5%[20]. - The net cash flow from operating activities for the current period was ¥938,413,241.57, down 59.3% from ¥2,303,661,711.51 in the previous period[26]. - The cash and cash equivalents at the end of the period stood at ¥2,105,442,764.51, down from ¥2,880,227,808.05, a decrease of approximately 26.9%[26]. - The company's inventory decreased to ¥604,946,621.32 from ¥902,196,386.55, a decline of approximately 32.9%[20]. - The total assets at the end of the reporting period were ¥9,089,590,388.73, a decrease of 10.40% from the end of the previous year[3]. - As of September 30, 2023, the total assets of the company amounted to ¥9,089,590,388.73, a decrease from ¥10,144,292,774.55 at the beginning of the year, representing a decline of approximately 10.4%[20]. - Accounts receivable decreased by 51.62% to ¥704,720,010.53, reflecting improved sales collection during the period[71]. - Other current assets increased by 44.06% to ¥79,867,065.37, mainly due to an increase in deductible VAT input tax and prepaid corporate income tax[71]. Liabilities and Borrowings - The company’s long-term borrowings increased by 133.94% to ¥732,016,816.49, primarily due to the increase in credit, mortgage, and pledge loans[6]. - The total liabilities amounted to approximately 2.83 billion yuan, compared to 3.67 billion yuan in the previous period, indicating a reduction in total liabilities[44]. Client and Project Activity - The company served approximately 300 global clients in small molecule API CDMO services, acquiring 77 new clients, with a total of 592 signed projects, a year-on-year increase of about 32%[14]. - The company’s new formulation team provided CDMO services to 80 clients, achieving a new order amount of approximately ¥144 million, a year-on-year increase of about 211%[15]. - The company completed 11 process validation (PV) projects in the first three quarters, with 13 PV projects currently in progress[37]. - In the first three quarters, the company signed new orders worth approximately 58 million yuan in the gene cell therapy CDMO business, a decline of 46% year-on-year, with 44 new clients and 64 new projects introduced[39]. - The company achieved its first clinical project order in cell therapy during the third quarter, marking a significant milestone in its clinical project portfolio[39]. Investments and R&D - The company’s new R&D facility in New Jersey, USA, covering nearly 4,000 square meters, has been officially put into operation, enhancing the company's integrated service capabilities for APIs and formulations[40]. - The company established an ESG working group to enhance its ESG performance, identifying 19 material ESG issues for the 2023-2024 period[40]. - The company’s total non-current assets increased to ¥5,436,960,702.11 from ¥4,681,745,817.60, marking an increase of about 16.1%[20]. - Fixed assets increased by 30.12% to ¥2,758,798,976.91, driven by the completion of several construction projects including the CDMO factory and new R&D centers[71]. - Right-of-use assets rose by 83.42% to ¥425,210,598.07, due to new leased spaces for the Shanghai and U.S. R&D centers[71]. Tax and Financial Expenses - The company received CNY 174 million in tax refunds, a decrease of 48.63% compared to CNY 339 million in the previous year[29]. - The company’s income tax expense decreased by 69.02% to CNY 70.5 million, reflecting a reduction in taxable income due to decreased profitability[28]. - The company reported a financial expense of CNY -22.6 million, a decrease of 45.88% from CNY -41.8 million, mainly due to reduced exchange gains[28]. - The company’s investment income improved by CNY 11.5 million, a 53.68% increase compared to the previous year, due to increased gains from foreign exchange contracts[28]. Other Financial Metrics - The company reported a government subsidy of CNY 6,034,740.81 for the current period, totaling CNY 24,057,636.12 year-to-date[58]. - The fair value changes of trading financial assets resulted in a gain of CNY 7,183,745.24 for the current period, with a total of CNY 18,507,688.51 year-to-date[58]. - Non-current asset disposal losses amounted to CNY -1,849,693.19 for the current period, with a total of CNY -9,791,077.96 year-to-date[58]. - The company experienced a foreign currency translation gain of CNY 10,405,734.90 for the current period, compared to CNY 29,698,754.81 year-to-date[50]. - The net other comprehensive income attributable to the parent company is CNY -5,535,777.66 for the current period, down from CNY -25,758,717.27 year-over-year[50]. - The total non-operating income and expenses, excluding normal business-related items, resulted in a net gain of CNY 7,432,722.91 for the current period[58]. - The company has implemented new accounting standards starting from 2023, affecting the financial reporting[52].